HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Launches Neutrogena Bright Boost, Children's Tylenol Dissolve Packs

Executive Summary

Neutrogena Bright Boost line launches with technology borrowed from J&J's recently acquired NeoStrata high-end skin care line, worldwide consumer health chief Thibaut Mongon says. J&J also launches Children’s Tylenol Dissolve Packs.

You may also be interested in...



J&J’s Aveeno Hair-Care Relaunch Per Vogue Model Helps Drive Consumer Q2 Improvements

Company leadership has said that Vogue International – the maker of OGX and Maui Moisture hair care that J&J acquired in 2016 – would serve as a model for innovations across other brands. Strategy appears to be paying off, contributing to gains in J&J's Consumer division, which also benefited in the second quarter from Zyrtec allergy treatment and children’s Tylenol and Motrin.

People Round-Up: Appointments At Afipa, J&J, Stada, WSMI, And Karo

J&J Consumer has a new chairman, Stada UK gets a permanent head, and Karo names its next CEO. On the association front, France's Afipa and the WSMI elect new leaders.

Rapid Release Gels, Arthritis Formulation Put Tylenol In US OTC Analgesic Lead

Tylenol brand consumption grows 10% on sales of Rapid Release Gel and Tylenol Arthritis, reaching top spot among analgesic products in the US, J&J says. Retailers' inventory builds as a result of prior-year supply constraints driven by Hurricane Maria also helped drive growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel